Infertility
is a global health issue as its affects both men and women.
Infertility in females occur due to increasing age, polycystic
ovarian syndrome (PCOS), obesity, and multiple miscarriages whereas
in males infertility occur due to erectile dysfunction, low sperm
count, abnormal sperms, etc. Increasing prevalence of infertility is
expected to propel demand for the infertility drugs. According to
World Health Organization (WHO) 2012 report, infertility affects one
out of four couples in emerging economies. Many researchers are
working towards finding an efficient treatment for the infertility.
For instance, in 2018 at Ben-Gurion University (BGU), Israel
researchers were developing a new, single-dose infertility treatment
based on a new compound. The new treatment, developed by the BGU
researchers, stimulates the expression of the telomerase and
re-elongates the telomeres, protecting the cells from damage.
Request
Sample of Report:
https://www.coherentmarketinsights.com/insight/request-sample/2665
The
global infertility drugs market size was valued at US$ 3.8 billion in
2017, and is expected to witness a CAGR of 5.8% over the forecast
period (2019 – 2026).
Increasing
Research & Development for More Effective Treatment with Lesser
Side-Effects to Reduce Infertility is expected to Drive Growth of the
Infertility Drugs Market
The
infertility drugs market size is expected to witness significant
growth, owing to the rising research and developmental studies for
more effective treatment to achieve pregnancy and live births. For
instance, in 2014, a team of researchers at National Institutes of
Health’s (NIH) Eunice Kennedy Shriver National Institute of Child
Health and Human Development (NICHD) found that women treated with
Letrozole have high rates of ovulation and live births than women
treated with the standard drug, Clomiphene. Furthermore, among women
who received Letrozole, 27.5% of them eventually had a live birth and
women who received clomiphene, only 19.1% them experienced a live
birth. The cumulative ovulation rate was higher for the Letrozole
group, with ovulation occurring 61.7% of the time, and the women in
the clomiphene group ovulated 48.3% of the time.
Infertility
Drugs Market - Regional Insights
On
the basis of region, the global infertility drugs market is segmented
into North America, Latin America, Europe, Asia Pacific, Middle East,
and Africa. North America is expected to hold a dominant position in
the global infertility drugs market size, owing to the rising number
of new Food and Drug Administration (FDA) infertility drug approvals
over the forecast period. For instance, in 2018, Zydus Cadila
launched generic Vardenafil Hydrochloride tablets used for the
treatment of erectile dysfunction in the U.S. The company has
launched the tablets in the strengths of 2.5 mg, 5 mg, 10 mg and 20
mg.
Infertility
Drugs Market - Competitive Landscape
Key
players operating in the global infertility drugs market include
Merck & Co., Ferring Pharmaceuticals, LIVZON Pharmaceutical Group
Inc., Abbott Laboratories, Bayer AG, and Zydus Pharmaceuticals.
Detailed
Segmentation:
Global
Infertility Drugs Market, By Drug Type:
-
Clomiphene citrate
-
Sex hormones
-
Estrogen
-
Progesterone
-
Testosterone
-
Gonadotropins
-
Bromocriptine
-
Cabergoline
-
Imipramine
-
Letrozole
-
Metformin
Global
Infertility Drugs Market, By Route of Administration:
-
Oral
-
Intravenous
-
Subcutaneous
-
Intramuscular
Browse
In-Depth Analysis Research Report:
https://www.coherentmarketinsights.com/market-insight/infertility-drugs-market-2665
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment